You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星基金會聯合復星醫藥及真實生物向農村地區捐贈價值1億元新冠口服藥阿茲夫定
格隆匯1月9日丨上海復星公益基金會(下稱“復星基金會”)今日聯合上海復星醫藥(集團)股份有限公司及河南真實生物科技有限公司宣佈向中國農村地區捐贈價值1億元人民幣的新冠口服藥阿茲夫定。這批藥品將分階段捐贈至中西部農村地區,覆蓋180個縣。阿茲夫定是國內首個具有完全自主知識產權的口服小分子新冠病毒感染治療藥物,於2022年7月25日獲國家藥監局附條件批准上市。2022年8月9日,國家衞生健康委辦公廳、國家中醫藥局辦公室將阿茲夫定納入《新型冠狀病毒肺炎診療方案(第九版)》,同時國家醫保局也將阿茲夫定納入醫保。2023年1月6日阿茲夫定再次被納入第十版《新型冠狀病毒感染診療方案》。自2022年8月以來,阿茲夫定已陸續配送至全國31個省市自治區使用。阿茲夫定作用機制明確,治療效果確切。真實世界數據顯示,儘早抗病毒治療對老人或有進展為重症高風險因素的患者獲益更多。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account